The study includes more than 500 men with late-stage prostate cancer who have not benefited from drugs that sharply lower testosterone -- the male sex hormone which fuels progression of the cancer.
Seattle-based Dendreon has said it aims to seek U.S. approval of the medicine soon afterward if the trial shows at least a 22 percent reduced risk of death, versus a placebo.
I'm hoping for good information because those late-stage prostate cancer victims have only one other therapy to choose from and it is like living death from what I hear. Provenge is supposed to prolong their lives fairly comfortably for months and could lead to a whole new field of cancer-killing therapeutic vaccines.
These things actually allow the immune system itself to fight against the cancer. I'm always amazed how well the body heals itself and it seems that Provenge could be the first in a series of drugs that help the body do this. You figure a cancer patient would rather have their own body killing the cancer instead of being bombarded with radiation and getting sick because of it.
No comments:
Post a Comment